New drug combo for drug-resistant TB (quabodepistat)
Part of Infections, Lungs & breathing clinical trials.
This study tests a new oral medication combination (quabodepistat with other drugs) for people with drug-resistant pulmonary TB. It aims to find a shorter, safer, and more effective treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 14 years old and weigh at least 66 pounds (30 kg).
- You have drug-resistant tuberculosis (TB) that is confirmed by a special test (Xpert MTB/RIF Ultra).
- You can provide a sputum (phlegm) sample for testing.
- If you could become pregnant, you must use two reliable birth control methods during treatment and for 12 weeks after the last dose.
- You do not have serious heart, liver, kidney, nerve, or bleeding problems, and your lab test results are within safe limits.
- You are not currently taking certain other TB medicines or experimental drugs, and you have not taken them in the past 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of drugs for people with active tuberculosis who have not been treated before. It aims to find a better way to treat TB, even if the bacteria are resistant to some drugs.
This trial tests new combinations of TB medicines for people with active lung TB that is sensitive to standard drugs. It aims to find safer, shorter treatments that work just as well or better than current options.
This study tests different ways to treat active lung TB that is not resistant to rifampicin. It aims to find the best treatment duration and combination to cure TB and prevent it from coming back.
This study tests a new combination of two existing medicines (pyrazinamide and hydroxychloroquine) to see if it works as well as the current standard treatment for TB. If it works, it could mean fewer pills or a shorter treatment for patients with drug-sensitive TB.
This Phase 2 study tests treatment for people with newly diagnosed, drug-susceptible pulmonary (lung) tuberculosis (TB). It aims to see whether the study treatment works well and is safe for curing TB.
This trial tests a new, all-oral, shorter treatment regimen for tuberculosis that is resistant to rifampicin, a key antibiotic. It may offer a more convenient and effective option for patients with this difficult-to-treat infection.
Hear when a new Pulmonary Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.